BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 20056007)

  • 1. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
    Muggerud AA; Rønneberg JA; Wärnberg F; Botling J; Busato F; Jovanovic J; Solvang H; Bukholm I; Børresen-Dale AL; Kristensen VN; Sørlie T; Tost J
    Breast Cancer Res; 2010; 12(1):R3. PubMed ID: 20056007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors.
    Klajic J; Fleischer T; Dejeux E; Edvardsen H; Warnberg F; Bukholm I; Lønning PE; Solvang H; Børresen-Dale AL; Tost J; Kristensen VN
    BMC Cancer; 2013 Oct; 13():456. PubMed ID: 24093668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter CpG island hypermethylation during breast cancer progression.
    Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
    Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
    Dejeux E; Rønneberg JA; Solvang H; Bukholm I; Geisler S; Aas T; Gut IG; Børresen-Dale AL; Lønning PE; Kristensen VN; Tost J
    Mol Cancer; 2010 Mar; 9():68. PubMed ID: 20338046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.
    Lin Q; Geng J; Ma K; Yu J; Sun J; Shen Z; Bao G; Chen Y; Zhang H; He Y; Luo X; Feng X; Zhu J
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1675-84. PubMed ID: 19506903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features.
    Pang JM; Deb S; Takano EA; Byrne DJ; Jene N; Boulghourjian A; Holliday A; Millar E; Lee CS; O'Toole SA; Dobrovic A; Fox SB
    Breast Cancer Res; 2014 Oct; 16(5):423. PubMed ID: 25331261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review.
    Lu YM; Cheng F; Teng LS
    Sci Rep; 2016 Sep; 6():32723. PubMed ID: 27620353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma.
    Kang JH; Kim SJ; Noh DY; Park IA; Choe KJ; Yoo OJ; Kang HS
    Lab Invest; 2001 Apr; 81(4):573-9. PubMed ID: 11304577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
    Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
    Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer.
    Zikan M; Bohm J; Pavlista D; Cibula D
    Clin Transl Oncol; 2011 Sep; 13(9):652-5. PubMed ID: 21865136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
    Verschuur-Maes AH; de Bruin PC; van Diest PJ
    Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.
    Fleischer T; Frigessi A; Johnson KC; Edvardsen H; Touleimat N; Klajic J; Riis ML; Haakensen VD; Wärnberg F; Naume B; Helland A; Børresen-Dale AL; Tost J; Christensen BC; Kristensen VN
    Genome Biol; 2014; 15(8):435. PubMed ID: 25146004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
    Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
    Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
    Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of DNA methylation status in early stages of breast cancer development.
    van Hoesel AQ; Sato Y; Elashoff DA; Turner RR; Giuliano AE; Shamonki JM; Kuppen PJ; van de Velde CJ; Hoon DS
    Br J Cancer; 2013 May; 108(10):2033-8. PubMed ID: 23652305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.